Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Combined Deficits for Health Insurance Societies Remain at Record-High Level
April 27, 2009
- MEDICAL DEVICE NEWS IN BRIEF
April 27, 2009
- No Progress on Discussions on Online Sales of OTC Drugs
April 27, 2009
- Taiyo Acquires Schering-Plough's Kasukabe Plant
April 27, 2009
- Korosho Proposes New Policy for Approval of Generics of Drugs Covered by Valid Use Patents
April 27, 2009
- R&D NEWS IN BRIEF
April 27, 2009
- CoreMed Expands Drug Development Support Services in Europe
April 27, 2009
- Potential Biomarker for Oxaliplatin Discovered: Prof. Tanigawara
April 27, 2009
- REGULATORY NEWS IN BRIEF
April 27, 2009
- 40 Medical Bills for Zyprexa Rejected due to Problems such as Overdoses
April 20, 2009
- Soaring Medical Expenses Are Mainly due to Drugs: Dr Nakagawa
April 20, 2009
- Some Med Facilities Do Not Apply for KRAS Gene Test as Senshin-Iryo
April 20, 2009
- Additional Economic Stimulation Measures Target Unapproved Drugs
April 20, 2009
- Lifestyle Intervention May Be as Effective as Medication in Japanese with Early Diabetes: DIANA Study
April 20, 2009
- CDFS to Review Japan's First Ca Blocker + ARB Combination
April 20, 2009
- Council on Regulatory Reform Calls For Continued Permission of Online Sale of OTC Drugs
April 20, 2009
- 20% of Hospitals in Shiga Pref. Prohibit Use of Generics as a Rule
April 20, 2009
- Kowa, Apo Plus Station Creates "Career & Leaps" to Support Marketing of OTC Drugs
April 20, 2009
- Kissei's Urief Launched in the US
April 20, 2009
- Alpha MOS Sets Up Japanese Subsidiary
April 20, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…